Hasegawa a high profile champion for the industry at Davos
This article was originally published in Scrip
As the World Economic Forum's annual meeting gets underway in Davos, Switzerland, the research-based pharmaceutical industry can rest easy that it is being represented at the highest level by a clear advocate of innovation.
You may also be interested in...
Japan approval for BTK inhibitor marks new indication but in a small niche market, while another clearance may help extend Latuda's commercial life.
Novel antibody-drug conjugate receives approval in Japan for second-line breast cancer, providing another push to Japanese firm’s strategic plan to build up its oncology operations.
Collaboration with fundraising Tokyo-based venture builds mid-sized firm's interest in cell-based therapies in a highly supportive regulatory environment.